WO2011149250A3 - 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 - Google Patents
트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2011149250A3 WO2011149250A3 PCT/KR2011/003801 KR2011003801W WO2011149250A3 WO 2011149250 A3 WO2011149250 A3 WO 2011149250A3 KR 2011003801 W KR2011003801 W KR 2011003801W WO 2011149250 A3 WO2011149250 A3 WO 2011149250A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- derivative
- rhenium
- label
- angiogenesis
- diagnosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/06—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180031236.6A CN102985413B (zh) | 2010-05-24 | 2011-05-24 | 三羰基锝-99m或铼-188标记的环RGD衍生物、其制备方法和包含所述衍生物作为活性成分用于诊断或治疗血管发生相关疾病的药物组合物 |
JP2013512534A JP5774687B2 (ja) | 2010-05-24 | 2011-05-24 | トリカルボニルテクネシウム−99mまたはレニウム−188標識サイクリックRGD誘導体、その製造方法及びそれを有効成分として含む新生血管関連疾患の診断または治療用薬学的組成物 |
US13/699,511 US9439986B2 (en) | 2010-05-24 | 2011-05-24 | Tricarbonyl technetium-99m, rhenium-185/187, or rhenium-188 labeled cyclic RGD derivatives and uses thereof |
EP11786882.8A EP2583966B1 (en) | 2010-05-24 | 2011-05-24 | Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100048289 | 2010-05-24 | ||
KR10-2010-0048289 | 2010-05-24 | ||
KR1020110043544A KR101383655B1 (ko) | 2010-05-24 | 2011-05-09 | 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
KR10-2011-0043544 | 2011-05-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011149250A2 WO2011149250A2 (ko) | 2011-12-01 |
WO2011149250A3 true WO2011149250A3 (ko) | 2012-03-22 |
Family
ID=45396864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/003801 WO2011149250A2 (ko) | 2010-05-24 | 2011-05-24 | 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US9439986B2 (ko) |
EP (1) | EP2583966B1 (ko) |
JP (1) | JP5774687B2 (ko) |
KR (1) | KR101383655B1 (ko) |
CN (1) | CN102985413B (ko) |
WO (1) | WO2011149250A2 (ko) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE063437T2 (hu) | 2013-09-24 | 2024-01-28 | Fujifilm Corp | Nitrogént tartalmazó vegyületet vagy sóját vagy fémkomplexét tartalmazó gyógyászati készítmény |
WO2016153054A1 (ja) | 2015-03-25 | 2016-09-29 | 富士フイルム株式会社 | 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体 |
CN106474495B (zh) * | 2016-11-21 | 2019-07-09 | 中国医学科学院阜外医院 | 含亚氨基二乙酸的99mTc标记的RGD多肽肿瘤诊断药物及其制备方法 |
KR102250737B1 (ko) * | 2020-06-01 | 2021-05-11 | 주식회사 비아이케이테라퓨틱스 | 약물 전달과 내재화 효율이 강화된 약물복합체 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080219921A1 (en) * | 2004-10-04 | 2008-09-11 | Rajiv Bhalla | Novel Technetium and Rhenium Complexes. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8512675B2 (en) * | 2003-04-29 | 2013-08-20 | Mallinckrodt Llc | N and/or Nα derivatized, metal and organic protected L-histidine for coupling to biomolecules for highly efficient labeling with [M(OH2)3 (CO)3]+ by fac coordination |
CN101474415B (zh) * | 2009-01-16 | 2011-09-28 | 北京大学 | 用于integrinαvβ3阳性肿瘤的RGD多肽放射性药物及其制备方法 |
KR101200049B1 (ko) * | 2012-05-14 | 2012-11-13 | 한국원자력연구원 | 테크네튬-99엠 트리카보닐 표지 글리신 단량체 또는 올리고머 활용 생리활성분자를 이용한 프로브의 제조방법 및 이를 포함하는 영상제 조성물 |
-
2011
- 2011-05-09 KR KR1020110043544A patent/KR101383655B1/ko active IP Right Grant
- 2011-05-24 JP JP2013512534A patent/JP5774687B2/ja active Active
- 2011-05-24 WO PCT/KR2011/003801 patent/WO2011149250A2/ko active Application Filing
- 2011-05-24 EP EP11786882.8A patent/EP2583966B1/en not_active Not-in-force
- 2011-05-24 CN CN201180031236.6A patent/CN102985413B/zh active Active
- 2011-05-24 US US13/699,511 patent/US9439986B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080219921A1 (en) * | 2004-10-04 | 2008-09-11 | Rajiv Bhalla | Novel Technetium and Rhenium Complexes. |
Non-Patent Citations (3)
Title |
---|
JUNG, GYEONG HO ET AL.: "Favorable Biokinetic and Tumor-Targeting Properties of 99mTc-Labeled Glucosamino RGD and Effect ofPaclitaxel Therapy", JOURNAL OF NUCLEAR MEDICINE, vol. 47, no. 12, 2006, pages 2000 - 2007 * |
LEE, BYEONG CHEOL ET AL.: "Synthesis of Tc-99m labeled glucosamino-Asp-cyclic (Arg- Gly-Asp-D-Phe-Lys) as a potential angiogenesis imaging agent", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 15, no. 24, 2007, pages 7755 - 7764, XP022302070, DOI: doi:10.1016/j.bmc.2007.08.054 * |
SUSANA ALVES ET AL.: "In Vitro and In Vivo Evaluation of a Novel 99mTc (CO)3- Pyrazolyl Conjugate of cyclo-(Arg-Gly-Asp-D-Tyr-Lys)", BIOCONJUGATE CHEMISTRY, vol. 18, no. 2, 2007, pages 530 - 537 * |
Also Published As
Publication number | Publication date |
---|---|
CN102985413B (zh) | 2016-04-20 |
US9439986B2 (en) | 2016-09-13 |
EP2583966A2 (en) | 2013-04-24 |
JP5774687B2 (ja) | 2015-09-09 |
KR20110128732A (ko) | 2011-11-30 |
US20130064766A1 (en) | 2013-03-14 |
EP2583966B1 (en) | 2016-08-10 |
WO2011149250A2 (ko) | 2011-12-01 |
CN102985413A (zh) | 2013-03-20 |
JP2013533852A (ja) | 2013-08-29 |
EP2583966A4 (en) | 2013-11-13 |
KR101383655B1 (ko) | 2014-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
WO2009043448A3 (en) | Neuromedin u-25 and neuromedin s as therapeutic agents | |
WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
JP2015524444A5 (ko) | ||
RU2020121715A (ru) | Синтез эластического волокна in vivo | |
JP2016539921A5 (ko) | ||
WO2011052888A3 (ko) | (3-플루오로-2-히드록시)프로필 작용기가 도입된 아릴 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물 | |
WO2009046832A3 (en) | Short peptides used in medicine | |
WO2011149250A2 (ko) | 트리카르보닐 테크네슘-99m 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 | |
JP2019530706A5 (ko) | ||
WO2009033660A3 (en) | Use of octreotide as a therapeutic agent | |
WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
Lin et al. | Phase I trial with a combination of docetaxel and 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer | |
RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
WO2009033749A3 (en) | Use of thymopentin as a therapeutic agent | |
RU2010140888A (ru) | Улучшенные противораковые терапии | |
RU2013150192A (ru) | Метапневмовирус птиц в онколизисе | |
JP2014502608A5 (ko) | ||
EP2402021A1 (en) | Pharmaceutical composition for treating or releiving inflammatory bowel disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180031236.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11786882 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13699511 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2013512534 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011786882 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011786882 Country of ref document: EP |